Cargando…
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an acquired highly prothrombotic disorder in which thrombo-inflammatory antiphospholipid antibodies (aPL) cause thrombosis via multiple mechanisms, including endothelial damage and activation. Obstetric complications in APS are caused by placental thrombosis, infla...
Autores principales: | Arachchillage, Deepa J., Laffan, Mike, Pericleous, Charis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866802/ https://www.ncbi.nlm.nih.gov/pubmed/36674847 http://dx.doi.org/10.3390/ijms24021331 |
Ejemplares similares
-
Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom
por: Arachchillage, Deepa J, et al.
Publicado: (2022) -
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
por: Arachchillage, Deepa R. J., et al.
Publicado: (2020) -
Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
por: Cousins, Laura, et al.
Publicado: (2015) -
Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
por: Calcaterra, Ilenia, et al.
Publicado: (2021) -
Cerebral vein thrombosis after ChAdOx1 nCov‐19 vaccination: Long‐term outcome of four patients
por: Arachchillage, Deepa J., et al.
Publicado: (2022)